(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
@ $5.26
发出时间: 15 Feb 2024 @ 01:24
回报率: -27.38%
上一信号: Feb 13 - 01:29
上一信号:
回报率: -3.66 %
Live Chart Being Loaded With Signals
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer...
Stats | |
---|---|
今日成交量 | 422 012 |
平均成交量 | 897 670 |
市值 | 140.11M |
EPS | $0 ( 2024-03-27 ) |
下一个收益日期 | ( $0 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.75 |
ATR14 | $0.00700 (0.18%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-01 | Toutain Stephan | Buy | 200 000 | Employee Stock Option (Right to Buy) |
2024-05-01 | Toutain Stephan | Buy | 0 | |
2024-01-22 | Shepard Kirk V. | Buy | 200 000 | Employee Stock Option (Right to Buy) |
2024-01-22 | Shepard Kirk V. | Buy | 0 | |
2023-12-04 | Boesgaard Lars | Buy | 200 000 | Employee Stock Option (Right to Buy) |
INSIDER POWER |
---|
77.08 |
Last 92 transactions |
Buy: 4 991 106 | Sell: 920 084 |
音量 相关性
PDS Biotechnology Corp 相关性 - 货币/商品
PDS Biotechnology Corp 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-57 326.00 (0.00 %) |
EPS: | $-1.390 |
FY | 2023 |
营收: | $0 |
毛利润: | $-57 326.00 (0.00 %) |
EPS: | $-1.390 |
FY | 2022 |
营收: | $0 |
毛利润: | $-49 078.00 (0.00 %) |
EPS: | $-1.430 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-0.660 |
Financial Reports:
No articles found.
PDS Biotechnology Corp
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。